19 results about "Carboxypeptidase" patented technology

The application discloses a kind of selectively targeted PSMA's biomimetic nanoparticles and its preparation method and application.This application simulates the glutamic acid substrate of carboxypeptidase and designs new functional monomer N-acrylamido glutaric acid and N-acrylamido succinic acid, a series of targeted PSMA's biomimetic nanoparticles with high affinity and selectivity to PSMA are synthesized using new monomer.The nanoparticle has low cost, higher stability, longer service life and stronger ability to resist harsh environment, overcomes the shortcomings of high cost, low preparation efficiency, long screening cycle, difficult to save and other defects of protein antibody.This application synthesizes water-soluble carbon dots with near-infrared fluorescence and photothermal properties, combined with the targeted PSMA's biomimetic nanoparticles, can replace protein antibody, nuclide imaging molecule and be used for targeted recognition of tumor cells and effective fluorescence imaging to early diagnose cancer, further kill tumor cells through photothermal therapy.

The present invention generally relates to a method of producing a therapeutic protein of interest secreted from host cells cultured in a bioreactor through adding a carboxypeptidase to the cell culture.

The application provides a longan peptide preparation method, product and application, and relates to the technical field of bioactive peptide processing. The longan peptide preparation method comprises the following steps: grinding longan kernels, adding water, and performing first enzyme hydrolysis to obtain an enzyme hydrolysate; the enzyme hydrolysate is inactivated, the pH value is adjusted to 8-9, stirring is performed at 30-40 DEG C, centrifugation and dialysis are performed, a supernatant is obtained, the pH value of the supernatant is adjusted to 4-6, and centrifugation is performed after standing to obtain longan kernel protein; the longan kernel protein is subjected to second enzyme hydrolysis, then inactivated, filtered, concentrated, and dried to obtain the longan peptide; the first enzyme hydrolysis is enzyme hydrolysis using cellulase, acid protease and glutamine enzyme; and the second enzyme hydrolysis is enzyme hydrolysis using trypsin, papain and carboxypeptidase. The longan peptide prepared by the application can effectively inhibit alpha-glucosidase, and achieve a sugar control effect.

The invention discloses application of double-mutant zebrafish in preparation of a mast cell function defect animal model. The double-mutant zebra fish disclosed by the invention is cpa1- / -cpa5- / -double-mutant zebra fish, and is obtained by further knocking out a cpa1 gene on the basis of a cpa5- / -zebra fish mutant. According to the method, potential compensation effects of two key carboxypeptidases are eliminated at the same time, and the storage and release capacity of mast cell protease is remarkably weakened from the genetics level, so that the zebrafish animal model with the mast cell function defect, which is clear in phenotype and stable in function, is obtained. The animal model can be used for mast cell function mechanism research, related disease mechanism exploration and drug screening and evaluation, and has a good application prospect.

The present invention relates to a hydrolyzed collagen formulation for use in decreasing blood glucose. The hydrolyzed collagen is obtained by enzymatic hydrolysis of a collagen-containing material with a combination of enzymes comprising two or more enzymes selected from the group consisting of a neutral protease, a carboxypeptidase, and an aminopeptidase. The hydrolyzed collagen formulation is particularly suitable as a food supplement, such as for use in ameliorating hyperglycemia and / or a risk factor hyperglycemia.

The application discloses a functionalized sialic acid compound and a preparation method and application thereof, and has a structural formula: after being taken by tumor cells, the application is catalyzed by esterase and carboxypeptidase highly expressed in tumors, and butyric acid and PBA-Sia are released respectively; wherein, butyric acid, as a known tumor growth inhibitor, can play a role by regulating the cell cycle and inducing cell apoptosis; butyric acid has an inhibiting effect on various tumors; PBA-Sia, which is a high-binding force ligand of a B cell membrane protein CD22 site introduced to the surface of cancer cells through sugar metabolism, can enhance the recognition and attack ability of B immune cells to tumors; PBA-Sia on the surface of cancer cells and butyric acid released in cells synergistically inhibit tumor cell proliferation.

Conjugates of corticosteroids and GCPII inhibitors and their use in treating inflammatory bowel disease are disclosed.

This disclosure concerns production of product peptides with a target amino acid sequence by proteolysis of a recombinant polypeptide comprising specific protease recognition sites or chemical cleavage sequences. In some embodiments, the product peptide is released from repeating peptide units in the recombinant polypeptide by removal of intervening amino acid sequences by proteolysis by proteases that recognize sites within the intervening amino acid sequences and a carboxypeptidase, aminopeptidase, and / or further protease.

The invention relates to a method for purifying proteins having a tubulin carboxypeptidase activity from a biological extract, comprising polymerization / depolymerization cycle performed on a biological extract in presence of microtubules. The invention further relates to a peptidic based inhibitor for use in the treatment of a disorder involving altered microtubule detyrosination in an animal, wherein the peptidic based inhibitor comprises a peptidic moiety constituted of 1 to 20 amino acids, said peptidic moiety having an amino acid selected from Y or F at the C-terminal position, and wherein the peptidic based inhibitor inhibits at least partially a tubulin carboxypeptidase activity.

The invention discloses a compound enzyme enzymolysis protein nano solution capable of directionally adsorbing sodium glycylchenodeoxycholate as well as a preparation method and application of the compound enzyme enzymolysis protein nano solution. The preparation method comprises the following steps: soybean protein reacts under the action of flavourzyme, carboxypeptidase is added for enzymolysis, rotary evaporation and spray drying are performed, and protein nano particles are obtained; the method comprises the following steps: dissolving protein nanoparticles in water to obtain a water phase, dissolving beta-carotene in ethyl acetate to obtain an organic phase, mixing the water phase and the organic phase, dispersing at a high speed, homogenizing, and carrying out rotary evaporation to obtain a protein nano solution. The preparation method provided by the invention is simple in operation process, safe in material, high in cost performance and convenient for large-scale production.

Methods for reducing stress-induced hormone production and treating a disease, disorder, or condition associated with an increase in stress-induced hormones by administering a therapeutically effective amount of a glutamate carboxypeptidase II (GCPII) inhibitor to a subject in need of treatment are disclosed.

The present invention discloses the application of the carboxypeptidase 6 (CPA6) gene in regulating host resistance to bovine enterovirus (BEV). Using CRISPR / Cas9 gene editing technology, a bovine kidney cell line with CPA6 gene knockout and a cell model resistant to BEV virus infection were constructed. The results of virological detection showed that the proliferation rate of BEV in gene-knockout cells was significantly lower than that in wild-type cells, while complementing the CPA6 gene caused the antiviral effect of the cells to disappear, indicating that the CPA6 gene plays an important role in regulating host resistance to BEV infection. The present invention identified the function of the CPA6 gene at the cellular level and discovered for the first time that the gene can be used as a potential target for gene-edited animal design in disease-resistant breeding, prevention and treatment of BEV infection, which is of great significance for reducing drug abuse and avoiding epidemics.

The invention provides a compound enzyme preparation and application thereof in preparation of a cyperus esculentus beverage, the compound enzyme preparation comprises phospholipase A1, a compound enzyme A, a compound enzyme B, tannase and carboxypeptidase, the compound enzyme A comprises cellulase, pectinase, alpha-amylase and beta-glucosidase; the compound enzyme B comprises neutral protease and alkaline protease. According to the particularity of components of the cyperus esculentus, main components of the cyperus esculentus comprise a certain amount of phospholipid and tannin besides fat, starch, dietary fiber and protein, although the contents of the components are relatively low, the taste of the finished product can be influenced by the existence of the components, so that the beany flavor and bitter taste of the finished product are caused; and the taste of the beverage is greatly improved.

The invention discloses a promoter derived from bacillus subtilis, modification of the promoter and application of the promoter in efficient expression of carboxypeptidase. Three different constitutive strong promoters Pcarp-525, Pcarp-551 and Pcarp-1293, which are not reported yet, are separated from a bacillus subtilis 13932 genome for the first time, carboxypeptidase is expressed in bacillus subtilis 168, and the strong promoters are subjected to rational transformation, so that the strong promoters are obtained. The strong promoter subjected to rational modification is used for expression of carboxypeptidase, efficient expression of carboxypeptidase is successfully realized, and the enzyme activity finally reaches 239.21 Uml by combining layer-by-layer optimization of carbon source addition amount, fermentation temperature and inoculum size, and the overall amplification reaches 194.02% compared with the initial level before promoter modification. The promoter efficiently expresses carboxypeptidase in a bacillus subtilis system, and provides a core element for industrial production.

The present invention discloses an effective peptide segment of a carboxypeptidase inhibitor of Bombyx mori, the carboxypeptidase inhibitor of Bombyx mori and its application. The amino acid sequence of the effective peptide segment of the carboxypeptidase inhibitor of Bombyx mori is tyrosine-glycine-valine-serine. The amino acid sequence of the carboxypeptidase inhibitor of Bombyx mori is as shown in SEQ ID NO.2. The effective peptide segment overlaps with the position of the small molecule inhibitor tak-285. It is found that both the effective peptide segment and the carboxypeptidase inhibitor of Bombyx mori can significantly inhibit the proliferation of gastric cancer cells, and can be used as a medical use for gastric cancer, providing a new drug for the treatment of gastric cancer and providing the possibility for the development of anti-tumor drugs from insect-derived substances.

Inhibition of glutamate-carboxypeptidase-II in and around the neuromuscular junctions (NMJ) of aged subjects can reduce age related reduction in muscle mass and strength. Compositions and methods for treating sarcopenia have been developed. Hydroxylated dendrimers conjugated with glutamate-carboxypeptidase-II (GCPII) inhibitors are administered in an amount effective to reduce, delay or reverse one or more symptoms or markers of sarcopenia. The hydroxylated dendrimer conjugated to a glutamate-carboxypeptidase-II (GCPII) inhibitor is in a dosage unit effective to reduce glutamate and / or increase NAAG within and / or around muscle macrophage and neuromuscular junctions (NMJ) in the subject.

The subject matter provides methods and compositions for preventing or treating chemotherapy-induced peripheral neuropathy (CIPN) by modulating delta-2 tubulin accumulation in sensory neurons. The therapeutic approaches targeting enzymes that regulate delta-2 tubulin formation, such as cytosolic carboxypeptidases (CCP1 and CCP6), or enhancing tubulin re-tyrosination via tubulin tyrosine ligase (TTL).

The invention relates to siRNA (small interfering Ribonucleic Acid) for inhibiting carboxypeptidase B2 gene expression, a conjugate thereof, a pharmaceutical composition and application. The siRNA disclosed by the invention contains a positive-sense strand and an antisense strand, and each nucleotide in the siRNA is independently modified or unmodified nucleotide. The siRNA as well as the conjugate and the pharmaceutical composition thereof disclosed by the invention can be used for effectively treating and / or preventing diseases related to CPB2 gene overexpression.

The invention discloses serine type carboxypeptidase for inhibiting growth of blue-green algae and belongs to the technical field of biology and environmental protection, bacillus altitudinis FY1 is screened and separated from a rice field water sample, it is found that protein serine type carboxypeptidase exists in the FY1 in the peptidoglycan biosynthesis process, the nucleotide sequence of the protein serine type carboxypeptidase is shown as SEQ ID 0.1 in a sequence table, and the nucleotide sequence of the protein serine type carboxypeptidase is shown as SEQ ID NO. The serine type carboxypeptidase is targeted to cell walls of cyanobacteria, has an efficient splitting effect on the cyanobacteria, can kill harmful cyanobacteria and is used for treating cyanobacteria bloom.